We are live on
!
Find out more
PBM
Propel Bio Management Portfolio holdings
AUM
$159M
1-Year Est. Return
60.94%
This Fund
S&P 500
This Quarter
Est. Return
-0.95%
1 Year Est. Return
+60.94%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$159M
AUM Growth
+$41.5M
(+35%)
Cap. Flow
+$58M
Cap. Flow
% of AUM
36.57%
Top 10 Holdings %
Top 10 Hldgs %
58.29%
Holding
42
New
22
Increased
6
Reduced
6
Closed
4
Top Buys
| 1 |
UPB
Upstream Bio Inc
UPB
|
+$6.15M |
| 2 |
Corcept Therapeutics
CORT
|
+$5.53M |
| 3 |
Delcath Systems
DCTH
|
+$5.24M |
| 4 |
Vor Biopharma
VOR
|
+$4.44M |
| 5 |
Orchestra BioMed
OBIO
|
+$3.82M |
Top Sells
| 1 |
Nektar Therapeutics
NKTR
|
+$3.5M |
| 2 |
Viridian Therapeutics
VRDN
|
+$2.15M |
| 3 |
Regenxbio
RGNX
|
+$1.68M |
| 4 |
IVA
Inventiva
IVA
|
+$1.68M |
| 5 |
Oculis Holding
OCS
|
+$1.34M |
Sector Composition
| 1 | Healthcare | 80.98% |
| 2 | Energy | 19.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Plains GP Holdings
PAGP
$4.97B
| $30.2M | 19.02% |
1,272,360
| – | – |
|
2
Achieve Life Sciences
ACHV
$650M
| $11.4M | 7.17% |
3,786,425
| – | – |
|
3
Phathom Pharmaceuticals
PHAT
$881M
| $9.35M | 5.9% |
841,272
+100,354
| +14% | +$1.27M |
|
|
4
Delcath Systems
DCTH
$455M
| $9.16M | 5.77% |
979,698
+541,189
| +123% | +$5.24M |
|
|
5
Corcept Therapeutics
CORT
$9.62B
| $6.02M | 3.8% |
+147,828
| New | +$5.53M |
|
6
Abeona Therapeutics
ABEO
$415M
| $6.01M | 3.79% |
1,329,899
+499,119
| +60% | +$2.5M |
|
|
7
Vor Biopharma
VOR
$980M
| $5.59M | 3.52% |
+314,543
| New | +$4.44M |
|
8
Kyverna Therapeutics
KYTX
$473M
| $5.59M | 3.52% |
644,421
-22,245
| -3% | -$185K |
|
9
Milestone Pharmaceuticals
MIST
$158M
| $5.08M | 3.2% |
4,118,321
| – | – |
|
10
Celldex Therapeutics
CLDX
$3.01B
| $4.14M | 2.61% |
131,364
-22,936
| -15% | -$625K |
|
|
CMPS
11
Compass Pathways
CMPS
$1.8B
| $4.12M | 2.6% |
742,049
-119,729
| -14% | -$805K |
|
|
12
Viridian Therapeutics
VRDN
$2.1B
| $4.09M | 2.58% |
210,163
-72,368
| -26% | -$2.15M |
|
|
IVA
13
Inventiva
IVA
$1.06B
| $3.99M | 2.52% |
724,678
-275,322
| -28% | -$1.68M |
|
14
SAB Biotherapeutics
SABS
$277M
| $3.89M | 2.45% |
1,012,790
+359,909
| +55% | +$1.44M |
|
|
15
Orchestra BioMed
OBIO
$219M
| $3.83M | 2.41% |
+896,701
| New | +$3.82M |
|
16
4D Molecular Therapeutics
FDMT
$611M
| $3.58M | 2.26% |
+380,420
| New | +$3.31M |
|
|
17
Oculis Holding
OCS
$792M
| $3.28M | 2.07% |
122,223
-50,616
| -29% | -$1.34M |
|
18
Ocular Therapeutix
OCUL
$2.18B
| $3.23M | 2.03% |
+382,375
| New | +$3.64M |
|
|
UPB
19
Upstream Bio Inc
UPB
$396M
| $3.1M | 1.95% |
+341,779
| New | +$6.15M |
|
20
Aquestive Therapeutics
AQST
$496M
| $2.95M | 1.86% |
+710,988
| New | +$2.89M |
|
21
EyePoint Inc
EYPT
$1.16B
| $2.79M | 1.76% |
+215,825
| New | +$3.23M |
|
22
Trevi Therapeutics
TRVI
$2.58B
| $2.65M | 1.67% |
+223,802
| New | +$2.51M |
|
23
Zevra Therapeutics
ZVRA
$766M
| $2.64M | 1.66% |
282,418
+218,735
| +343% | +$1.97M |
|
24
Immunic
IMUX
$206M
| $2.62M | 1.65% |
+234,478
| New | +$2.1M |
|
25
Coherus Oncology
CHRS
$222M
| $2.41M | 1.52% |
+1,420,550
| New | +$2.52M |
|
Similar funds
OS
OC
JF
1L
USWIA
AWP
RWM
EWA